Xenon Pharmaceuticals Management
Management criteria checks 2/4
Xenon Pharmaceuticals' CEO is Ian Mortimer, appointed in Mar 2018, has a tenure of 6.67 years. total yearly compensation is $10.12M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth $1.90M. The average tenure of the management team and the board of directors is 4.3 years and 3.7 years respectively.
Key information
Ian Mortimer
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 6.7yrs |
| CEO ownership | 0.06% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.7yrs |
Recent management updates
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$165m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
Compensation vs Market: Ian's total compensation ($USD10.12M) is above average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: Ian's compensation has increased whilst the company is unprofitable.
CEO
Ian Mortimer (48 yo)
6.7yrs
Tenure
US$10,117,829
Compensation
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.7yrs | US$10.12m | 0.060% $ 1.9m | |
| Chief Financial Officer | 3.4yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | 0% $ 0 | |
| Chief Commercial Officer | 4.3yrs | US$2.76m | 0.0053% $ 166.8k | |
| Chief Medical Officer | 3.3yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 2yrs | US$3.55m | no data | |
| Executive Vice President of Human Resources | 5.2yrs | no data | no data | |
| Executive Vice President of Drug Discovery | 8.8yrs | US$545.00k | no data | |
| Executive Vice President of R&D Operations | 4.3yrs | no data | no data |
4.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: XENE's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.4yrs | US$10.12m | 0.060% $ 1.9m | |
| Independent Director | 1.3yrs | US$770.91k | no data | |
| Independent Director | 20.8yrs | US$560.09k | 0.038% $ 1.2m | |
| Independent Director | 4yrs | US$559.58k | 0% $ 0 | |
| Independent Director | 9.5yrs | US$561.42k | 0.0026% $ 83.4k | |
| Independent Chairman | 8.2yrs | US$588.37k | 0.033% $ 1.0m | |
| Independent Director | 1.3yrs | US$770.91k | no data | |
| Independent Director | 3.4yrs | US$548.57k | no data |
3.7yrs
Average Tenure
61.5yo
Average Age
Experienced Board: XENE's board of directors are considered experienced (3.7 years average tenure).